Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV's revenue rose 303.5% to €1.1 billion in fiscal 2025. Its operating margin was 26.5%, up from −68.3% a year earlier. Free cash flow was −€271 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2016 to 2025, earnings per share grew 17.5% a year and net income 21.9% a year, as new shares raised the share count by 39% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 4,703 | 4,094 | 3,684 | 3,118 | 2,998 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −14.8x | −19.0x | −49.9x | −206.7x | 285.3x |
| Current ratio | 8.6x | 8.1x | 9.0x | 10.0x | 20.1x |
| Quick ratio | 8.6x | 8.0x | 8.8x | 9.8x | 20.0x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −177.8% | −107.2% | 279.1% |
| Altman Z'' | 6.74 | 6.81 | 26.33 |
| Accruals ratio | 13.6% | 9.3% | 15.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | — | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Lakefront Biotherapeutics NV side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Lakefront Biotherapeutics NV | FY25 | 303.5% | 26.5% | −24.4% | — | — | — | |
| Novavax | FY25 | 64.7% | 40.3% | −22.3% | — | −1.0x | 5 | Compare |
| Legend Biotech | FY25 | 64.0% | −13.3% | −12.5% | −14.6% | — | 2 | Compare |
| Halozyme | FY25 | 37.5% | 33.6% | 46.1% | 19.2% | 4.2x | 5 | Compare |
| BioCryst Pharmaceuticals | FY25 | 94.1% | 39.0% | 39.4% | — | −0.8x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 130 | 127 | 279 | 835 | 478 | 234 | 241 | 240 | 276 | 1,112 |
| Revenue growth | 227.4% | −1.9% | 119.3% | 199.6% | −42.7% | −51.0% | 2.9% | −0.6% | 15.0% | 303.5% |
| Gross profit | — | — | — | — | — | 233 | 229 | — | 241 | 1,082 |
| Research and development | 140 | 218 | 316 | 420 | 524 | 320 | 270 | 241 | 336 | 459 |
| Operating income | −12 | −90 | −47 | 369 | −179 | −172 | −131 | −88 | −188 | 295 |
| Net income | 54 | −116 | −29 | 150 | −305 | −103 | −218 | 212 | 74 | 321 |
| Diluted EPS (EUR) | 1.14 | −2.34 | −0.56 | 2.49 | −4.69 | −1.58 | −3.32 | 3.21 | 1.12 | 4.87 |
| Diluted shares (millions) | 47 | 50 | 52 | 58 | 65 | 66 | 66 | 66 | 66 | 66 |
| Cash flow | ||||||||||
| Cash from operations | 239 | −147 | −142 | 3,209 | −427 | −504 | −500 | −406 | −320 | −258 |
| Capital expenditure | 4 | 5 | 10 | 22 | 42 | 54 | 27 | 19 | 17 | 14 |
| Free cash flow | 235 | −152 | −153 | 3,186 | −470 | −558 | −528 | −425 | −337 | −271 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 115 | 7 | 0 | 0 |
| Stock-based compensation | 11 | 16 | 27 | 38 | 80 | 71 | 88 | 57 | 20 | 24 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 973 | 1,151 | 1,291 | 5,781 | 5,162 | 4,703 | 4,094 | 3,684 | 3,118 | 2,998 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 1,083 | 1,286 | 1,440 | 6,069 | 5,718 | 5,193 | 4,734 | 4,357 | 4,136 | 3,406 |
| Total liabilities | 325 | 274 | 225 | 3,193 | 3,047 | 2,550 | 2,208 | 1,562 | 1,239 | 171 |
| Shareholders' equity | 759 | 1,012 | 1,214 | 2,876 | 2,670 | 2,643 | 2,526 | 2,796 | 2,897 | 3,236 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | 99.3% | 95.0% | — | 87.3% | 97.3% |
| Operating margin | −8.9% | −70.7% | −16.9% | 44.2% | −37.4% | −73.2% | −54.3% | −36.8% | −68.3% | 26.5% |
| Net margin | 41.7% | −91.0% | −10.5% | 17.9% | −63.9% | −44.0% | −90.4% | 88.3% | 26.9% | 28.9% |
| Free cash flow margin | 181.4% | −119.9% | −54.9% | 381.6% | −98.3% | −238.1% | −218.8% | −177.2% | −122.2% | −24.4% |
| Rule of 40 (growth + FCF margin) | 408.8% | −121.8% | 64.4% | 581.2% | −141.0% | −289.1% | −215.9% | −177.8% | −107.2% | 279.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 9.6% | −13.1% | −2.6% | 7.3% | −11.0% | −3.9% | −8.4% | 8.0% | 2.6% | 10.5% |
| Return on assets | 7.1% | −9.8% | −2.1% | 4.0% | −5.2% | −1.9% | −4.4% | 4.7% | 1.7% | 8.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |